Becor Communications Inc. Announces Acquisition of Enhance Lifesciences Inc.

Business Editors & Health/Medical Writers

ENCINO, Calif.--(BUSINESS WIRE)--Feb. 11, 2003

Becor Communications Inc. (OTCBB:BCOI) today announced it has signed a definitive agreement to acquire 100% of all the outstanding shares of Enhance Lifesciences Inc., a privately held Delaware company. It is anticipated that the transaction will close on Feb. 28, 2003.

Enhance Lifesciences Inc. is an emerging biopharmaceutical company that is focused on the acquisition, development and commercialization of "Lifestyle Drugs" in the main therapeutic lifestyle disorder categories. The Company currently has six products in development targeted against Sexual Dysfunction, IVF, Depression, Anti-Cellulite, Anti-Aging and arthritis. These six initial categories have a combined projected marketplace value in excess of $29 billion by 2007 according to a recent report on the sector. Over the past ten years the pharmaceutical industry has spent over $20 billion in R&D on lifestyle drugs.

Enhance Lifesciences, with its strategy of developing its existing products and acquiring other late stage product candidates in the "Lifestyle Drugs" sector, will position itself to be at the forefront in the development of drugs that will improve and enhance the lifestyles of many patients. By focusing on this particular developing sector where there is the opportunity to acquire and develop potential "blockbuster" products, the company has the opportunity for exponential growth. Enhance's two lead products are planned to be the first to market lifestyle drugs in unsaturated sectors that meet unmet needs and that have the potential to make significant media impact and have potential blockbuster status.

Mr. Christopher Every, Enhance Lifesciences' President stated, "Our Company is in an industry that has great potential for rapid growth, and by being part of a publicly traded company, Enhance Lifesciences Inc. has positioned itself to gain better access to capital markets to expand our operations, and to grow our company through strategic acquisitions."

"We are extremely delighted to afford our shareholders the opportunity to participate in a company that has significant expansion capability," said Mr. Buddy Young, President of Becor Communications. "Enhance Lifesciences' strong management team combined with their excellent business model greatly improves the Company's potential for growth and profitability," added Mr. Young.

Additionally, pending shareholder approval, Advanced Knowledge, Inc., Becor's wholly owned subsidiary, will be spun off to Becor's shareholders of record on the day prior to the closing of the acquisition of Enhance Lifesciences. Advanced Knowledge produces and distributes workforce training videos throughout the world.

Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because these statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Specifically, factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to: risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and in Enhance Lifesciences' compounds under development in particular; the potential failure of Enhance Lifesciences' compounds under development to prove safe and effective for treatment of disease; uncertainties inherent in the early stage of Enhance Lifesciences' compounds under development; failure to successfully implement or complete clinical trials; failure to receive marketing clearance from regulatory agencies for our compounds under development; acquisitions, divestitures, mergers, licenses or strategic initiatives that change Enhance Lifesciences' business, structure or projections; the development of competing products; uncertainties related to Enhance Lifesciences' dependence on third parties and partners; and those risks described in Becor Communications Inc.'s filings with the SEC. Becor Communications Inc. and Enhance Lifesciences disclaims any obligation to update these forward-looking statements.